Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | USP8 | P40818 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3736581 | 0.84 | NTRK1 (0.51) | NTRK1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL7822017 | 0.79 | NTRK1 (0.51) | NTRK1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL7820788 | 0.79 | USP8 (0.42) | NTRK1USP8KDM4EKMT2AL3MBTL1 | |
| SCHEMBL3740972 | 0.78 | TOP1 (0.50) | PDE10AHSD17B10 | |
| SCHEMBL7820175 | 0.78 | TP53 (0.51) | KDM4ELMNAHSD17B10KMT2AL3MBTL1 | |
| SCHEMBL21451028 | 0.77 | TDO2 (0.46) | USP8KDM4EKMT2AL3MBTL1 | |
| SCHEMBL7811355 | 0.74 | NTRK1 (0.50) | NTRK1KDM4ELMNAKMT2A | |
| SCHEMBL31500243 | 0.72 | KDM4E (0.48) | AMY1APLA2G2AMAPK14CYP17A1CYP11B1 | |
| SCHEMBL8078210 | 0.71 | MAPK14 (0.53) | MDM2MAPK14USP8KMT2A | |
| SCHEMBL3738396 | 0.71 | ALOX15 (0.43) | KDM4ELMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829567-B2 | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2010-11-09 | — | — | US | disclosed |
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111987-A1 | Imino-Indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same | IMPA1, IMPDH1, IPO5 | AMY1A 1011/4885NTRK1 4732/4885PLA2G2A 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.